Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Molecular Genetic and Pathological Studies of Anal Tumors

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2012 by Stanford University.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Stanford University
ClinicalTrials.gov Identifier:
NCT00267787
First received: December 19, 2005
Last updated: July 5, 2012
Last verified: July 2012

December 19, 2005
July 5, 2012
September 2004
December 2012   (final data collection date for primary outcome measure)
Genetic analysis of blood sample as well as tissues , will provide us with any possible tumor marker for a better prognostic indicator. [ Time Frame: Annual assessment. ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00267787 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Molecular Genetic and Pathological Studies of Anal Tumors
Molecular Genetic and Pathological Studies of Anal Tumors

Study the Genetics of Anal Cancer

To determine the status of previously identified anal cancer molecular markers and any correlations with outcome as well as to discover new molecular biomarkers through correlating molecular data with clinical outcome. Study of tissue samples and cells from biopsies of your lesion and blood sample. We hope to learn the role genes and proteins may play in the development of anal cancer. Experiments will be performed using this tissue and blood, include analysis of DNA, analysis of RNA expression levels, analysis of protein levels of important gene products, and development of tissue culture cell lines.

Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

whole blood

Non-Probability Sample

Adult patients with anal cancer or high risk for anal cancer refered to Stanford.

  • Rectal Cancer
  • Colon Cancer
  • Colonic Neoplasms
  • Anal Cancer
Other: genetic analysis
standard of care
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
300
December 2013
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:Inclusion Criteria:

  • Patients with anal tumors
  • Undergoing surgery for elective colon and rectal surgery

Exclusion Criteria:No other patients other than adult patients with anal cancer or high risk for anal cancer refered to Stanford will be enrolled to the study. No Children will be included to the study

Both
18 Years and older
No
Contact: Moe Jalali (650) 724-4023 moej@stanford.edu
United States
 
NCT00267787
ANAL0001, 95340, ANAL0001
Yes
Stanford University
Stanford University
Not Provided
Principal Investigator: Mark Lane Welton Stanford University
Stanford University
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP